Grace Therapeutics (FRA:L8S) FFO


FRA:L8S Grace Therapeutics Inc FRA:L8S
31 GF Score
Price €2.78
! 2 Warning Signs
View Full Analysis

What is Grace Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

FRA:L8S
31GF Score
Grace Therapeutics Inc FRA:L8S
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Grace Therapeutics Business Description

Other Exchanges GRCE:USA
Address 103 Carnegie Center, Suite 300, Princeton, NJ, USA, 08540
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
31GF Score

Get the complete analysis for FRA:L8S

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.78
Price